Abraham Havron - Enlivex Therapeutics Independent Director

ENLV Stock  ILA 415.10  4.10  0.98%   

Director

Abraham Havron is Independent Director of Enlivex Therapeutics since 2014.
Age 71
Tenure 10 years
Phone(972) 2 6208070
Webwww.enlivex.com

Enlivex Therapeutics Management Efficiency

The company has return on total asset (ROA) of (0.1888) % which means that it has lost $0.1888 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.378) %, meaning that it generated substantial loss on money invested by shareholders. Enlivex Therapeutics' management efficiency ratios could be used to measure how well Enlivex Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.
Enlivex Therapeutics has accumulated 615 K in total debt with debt to equity ratio (D/E) of 0.01, which may suggest the company is not taking enough advantage from borrowing. Enlivex Therapeutics has a current ratio of 19.88, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Enlivex Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Enlivex Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Enlivex Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Enlivex to invest in growth at high rates of return. When we think about Enlivex Therapeutics' use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 6 records

DIRECTOR Age

Daphna KleinerIDI Insurance
57
Naomi ShapiroAnalyst IMS Investment
39
Blake LyonSkyline Investments
45
Avi DrechslerAnalyst IMS Investment
57
Efraim AvrahamAnalyst IMS Investment
64
Dalit BarakAnalyst IMS Investment
37
Enlivex Therapeutics Ltd. operates as a clinical stage immunotherapy company. Enlivex Therapeutics Ltd. was incorporated in 2005 and is headquartered in Nes Ziona, Israel. ENLIVEX THERAPEUTI operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 50 people. Enlivex Therapeutics (ENLV) is traded on Tel Aviv Stock Exchange in Israel and employs 71 people.

Management Performance

Enlivex Therapeutics Leadership Team

Elected by the shareholders, the Enlivex Therapeutics' board of directors comprises two types of representatives: Enlivex Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Enlivex. The board's role is to monitor Enlivex Therapeutics' management team and ensure that shareholders' interests are well served. Enlivex Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Enlivex Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Abraham Havron, Independent Director
Shai Novik, Executive Chairman of the Board
Dror Mevorach, Chief Executive Officer, Founder, Chief Scientific Officer
Shachar Shlosberger, Chief Financial Officer
Odelia BenShitrit, Head of Clinical Operations
Sangwoo Lee, Director
Oren Hershkovitz, Chief Executive Officer
Baruch Halpert, Director
Michel Habib, Director
Shai MBA, Ex Chairman
Pr MD, Founder Officer
Veronique AmorBaroukh, Head CMC
Shachar CPA, Chief Officer
Gili Hart, Independent Director
Brian Schwartz, Director
Bernhard Kirschbaum, Director
Sigal Arad, Director HR
Hyun Lee, Director

Enlivex Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Enlivex Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Information and Resources on Investing in Enlivex Stock

When determining whether Enlivex Therapeutics is a strong investment it is important to analyze Enlivex Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Enlivex Therapeutics' future performance. For an informed investment choice regarding Enlivex Stock, refer to the following important reports:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enlivex Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For information on how to trade Enlivex Stock refer to our How to Trade Enlivex Stock guide.
You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Please note, there is a significant difference between Enlivex Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enlivex Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enlivex Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.